Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

LAG-3 Antibody Relatlimab Combined With PD-1 Inhibition Improves PFS in Previously Untreated Melanoma

The randomized, double-blind phase 2/3 RELATIVITY-047 trial (NCT03470922) examining the experimental anti–LAG-3 antibody relatlimab plus nivolumab (Opdivo) versus nivolumab alone in patients with treatment-naïve metastatic or unresectable melanoma met its primary end point of progression-free survival, according to Bristol Myers Squibb who is responsible for developing the agent.1

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

In fifteen patients with stage 0–III melanoma, the numbers of CTCs were analyzed.

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Combos Lead Excitement in BRAF+ Melanoma, but More Pain Points are Ready to be Tackled

Therapeutic approaches to target the metabolic pathways, an enhanced understanding of how to utilize triplet regimens, and improving outcomes for patients with brain metastases are all areas being tackled in the setting of advanced BRAF-positive melanoma, explained Michael A. Davies, MD, PhD.